The Coronavirus Disease 2019 Pandemic is Associated with a Substantial Rise in Frequency and Severity of Presentation of Youth-Onset Type 2 Diabetes.

Authors:
Magge SN; Wolf RM; Pyle L; Brown EA; Benavides VC and 23 more

Journal:
J Pediatr

Publication Year: 2022

DOI:
10.1016/j.jpeds.2022.08.010

PMCID:
PMC9383958

PMID:
35985535

View on PubMed View on PMC View Publisher
Journal Information

Full Title: J Pediatr

Abbreviation: J Pediatr

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Pediatrics

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Cardiac Magnetic Resonance Findings of Coronavirus Disease 2019 (COVID-19) Vaccine-Associated Myope…
Dove ML; Slesnick TC; Oster ME and 3 more (2023) - Transparency Score: 3/6
The Impact of COVID-19 on Infant Maltreatment Emergency Department and Inpatient Medical Encounters.
Rebbe R; Reddy J; Kuelbs CL and 2 more (2023) - Transparency Score: 3/6
Comorbidities Associated with Hospitalization and Progression Among Adolescents with Symptomatic Co…
Campbell JI; Dubois MM; Savage TJ and 6 more (2022) - Transparency Score: 3/6
Effect of Outreach Messages on Adolescent Well-Child Visits and Coronavirus Disease 2019 Vaccine Ra…
Burkhardt MC; Berset AE; Xu Y and 2 more (2022) - Transparency Score: 4/6
Health Surveillance in a Down Syndrome Specialty Clinic: Implementation of Electronic Health Record…
Santoro SL; Howe YJ; Krell K and 2 more (2022) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Funding and Conflicts of Interest Disclosure L.H. is a site investigator for a type 2 diabetes treatment trial sponsored by Boehringer-Ingelheim; M.K. is a site investigator for type 2 diabetes treatment trials sponsored by Boehringer-Ingelheim and Janssen; B.M. has received investigator-initiated funding from Tandem Diabetes Care and Dexcom; A.S. is the site PI for trials sponsored by AstraZeneca, NovoNordisk, and Boehringer-Ingelheim; and R.W. has received investigator-initiated funding from 10.13039/100015769Dexcom; the other authors declare no conflicts of interest."

Evidence found in paper:

"Funding and Conflicts of Interest Disclosure L.H. is a site investigator for a type 2 diabetes treatment trial sponsored by Boehringer-Ingelheim; M.K. is a site investigator for type 2 diabetes treatment trials sponsored by Boehringer-Ingelheim and Janssen; B.M. has received investigator-initiated funding from Tandem Diabetes Care and Dexcom; A.S. is the site PI for trials sponsored by AstraZeneca, NovoNordisk, and Boehringer-Ingelheim; and R.W. has received investigator-initiated funding from 10.13039/100015769Dexcom; the other authors declare no conflicts of interest."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025